What Is Actually in AREDS2: Every Ingredient, Explained

The AREDS2 label reads like a short multivitamin. It is not one. Every amount on it was chosen for a trial, several are far above what you would obtain from food, and at least one ingredient is present only to counteract another.

Here is what is in it and why, ingredient by ingredient. For the trial these amounts came out of, see the study behind the formulation, and for which products actually carry all six, we read the labels.

Lutein and zeaxanthin: the only two that go to the macula

Start with these, because they are the reason the formulation changed and the only ingredients with a direct structural link to the tissue in question.

Your macula is not uniformly coloured. At its centre it holds a dense yellow pigment made of exactly three carotenoids: lutein, zeaxanthin, and meso-zeaxanthin, which the body makes from lutein. That pigment absorbs short-wavelength light before it reaches the photoreceptors and acts as an antioxidant in a tissue that badly needs one. It is a filter your body builds out of what you eat.

You cannot synthesise lutein or zeaxanthin. They come from dark leafy greens, egg yolk, and maize. The trial supplied 10 mg of lutein and 2 mg of zeaxanthin, which is a meaningful multiple of typical Western intake. That 5:1 ratio is not arbitrary; it approximates their relative abundance in the diet rather than in the macula itself, where zeaxanthin dominates at the very centre.

Vitamin C and vitamin E: the antioxidant pair

Both are here as antioxidants, and both are at amounts you would not reach through food.

Vitamin C at 500 mg is roughly five to eight times common daily reference intakes. It is water-soluble, so the body excretes what it does not use, which is why high doses are generally well tolerated. Vitamin E at 400 IU is the more striking number, well over twenty times typical intake, and it is fat-soluble, meaning it accumulates rather than washing out.

The rationale is the retina's chemistry. It combines intense light, very high oxygen consumption, and membranes rich in polyunsaturated fats, which is close to a worst case for oxidative damage. Whether high-dose antioxidants meaningfully counter that is precisely the question AREDS was built to answer, and the answer turned out to be yes but only in eyes already showing intermediate disease.

Zinc: the largest amount, and the least settled

Zinc at 80 mg is by far the biggest departure from dietary levels in the formulation, roughly seven to ten times normal intake. It is in there because zinc is highly concentrated in the retina and the retinal pigment epithelium, and because it is a cofactor for enzymes involved in handling oxidative stress.

AREDS2 also ran the useful experiment. One arm reproduced the formulation with zinc reduced from 80 mg to 25 mg. The reduction made no difference to how the formulation performed, and the trial did not find the lower dose produced fewer side effects either.

This is worth knowing because commercial products differ on exactly this number and present it as a differentiator. On the evidence it is not one. If 80 mg upsets your stomach, 25 mg is a reasonable practical choice, and you are not trading away efficacy to make it.

Copper: the ingredient that is not about your eyes

Copper at 2 mg is the most misunderstood item on the label, because it is not there for the retina at all.

Zinc and copper compete for the same absorption pathway in the gut. Sustained high-dose zinc can therefore drive copper down, and copper deficiency is not benign: it can cause anaemia and neurological problems. The trial included cupric oxide to make sure the intervention did not cure one thing while causing another.

That makes copper the single best quick test of whether a product was assembled by someone who read the trial. A high-zinc eye supplement with no copper has removed a safety component and kept the marketing.

What was tested and left out

Two absences on the label are as informative as anything present.

• Beta-carotene was in the original AREDS formula at 15 mg and was removed. Large trials had linked high-dose beta-carotene to increased lung-cancer risk in smokers, and AREDS2 confirmed that swapping it for lutein and zeaxanthin cost nothing in effect. We cover what changed between the two formulas in detail.
• Omega-3 fatty acids were tested in AREDS2 as an addition, and produced no further benefit. That is unusually clean evidence, and it is why DHA and EPA are not part of the formulation despite appearing on many eye supplements.

How these amounts compare to eating well

A reasonable question, and the answer is that they are not comparable, which is the point.

You are not going to eat your way to this formulation, and that is deliberate. It was designed as a pharmacological intervention that happens to be assembled from nutrients. It is also why improvising a version from separate bottles is a poor idea, and why the whole thing only makes sense for the specific group the trial actually studied.

Eating leafy greens and oily fish remains worth doing. It supports long-term eye health through a different and slower mechanism, and it is not a substitute for the formulation in people who need it, nor a reason to take the formulation if you do not.